SP001 Anti-CD40L Licensing: Class Safety Liability Unresolved, Binary Outcome Asset at $1.1B Valuation

Spero Licenses Innovent's Autoimmune Antibody in $1.1B Deal

Spero Therapeutics has licensed SP001, an investigational anti-CD40L antibody, from China-based Innovent Biologics for autoimmune diseases. The deal is valued at up to $1.1 billion, encompassing an upfront commitment, R&D, regulatory, and commercial milestones, plus tiered royalties on net sales. Spero gains exclusive global development rights outside Greater China and plans to initiate a Phase 2 study for IgG4-related disease in the second quarter of 2027. Innovent retains rights in Greater China, where it has completed early-stage trials and plans a Phase 2 Sjögren’s disease trial in early 2027. To fund SP001's development, Spero secured $105 million from Healthcare Royalty.

• Spero Therapeutics has entered a licensing agreement with Innovent Biologics for SP001, an anti-CD40L antibody, with a total deal value potentially reaching $1.1 billion. This sum includes an upfront payment, R&D, regulatory, and commercial milestones, alongside tiered royalties on net sales for Innovent, highlighting a significant investment in a promising autoimmune therapy.
• Under the terms, Spero obtains exclusive global development rights for SP001 outside of Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan. Spero plans to advance SP001 into a Phase 2 trial for IgG4-related disease in the second quarter of 2027, while Innovent will continue its development in Greater China, including a planned Phase 2 Sjögren’s disease trial in early 2027.
• To support the development of SP001, Spero Therapeutics has secured $105 million through a financing agreement with Healthcare Royalty. This funding is backed by an undisclosed portion of future sales-based milestones and royalty payments associated with Spero's GSK-partnered antibiotic, Utebzi, which recently received FDA approval for complicated urinary tract infection.

Addressing Unmet Needs in IgG4-Related Disease Treatment

Current treatment of IgG4-related disease (IgG4-RD) is constrained by a reliance on glucocorticoids as the primary therapeutic modality, despite their well-documented toxicity profile and the high rates of relapse observed upon dose tapering or withdrawal. The absence of highly specific diagnostic tests further complicates disease management, requiring clinicopathological correlation and potentially delaying initiation of appropriate therapy.

• Glucocorticoid toxicity and limited alternatives: Long-term systemic steroid use carries significant toxicity risk, particularly in elderly patients — a population disproportionately affected by IgG4-RD. Although initial steroid response rates are high (~97%), relapse occurs in approximately 50% of patients, and no glucocorticoid-sparing agent had received regulatory approval until very recently.

• High relapse rates and treatment resistance: Disease flares are commonly observed during steroid tapering or following discontinuation, with IgG4-related sclerosing cholangitis (IgG4-SC) identified as a significant independent predictor of relapse (P<0.01). Treatment resistance upon dose reduction further underscores the need for more durable therapeutic strategies.

• Undefined optimal maintenance therapy: The optimal approach to maintenance immunosuppression has not been established. Conventional synthetic DMARDs — including mycophenolate mofetil, leflunomide, azathioprine, and methotrexate — are frequently employed as steroid-sparing agents, yet comparative evidence supporting their use remains limited.

• Off-label status of rituximab: Despite demonstrated high efficacy as both first-line and rescue therapy — including in IgG4-related coronary artery involvement without concomitant glucocorticoids — rituximab remains off-label in most regions, with no randomized controlled trials formally evaluating its efficacy in this setting.

• Risk of irreversible organ damage: If undertreated, IgG4-RD can result in permanent organ damage, decreased quality of life, and increased mortality. Disease progression, including relapse and advancement of coronary lesions, has been documented despite active treatment in some cases.

• Complications from immunosuppressive therapy: Immunosuppressive regimens carry their own procedural risks; reported complications include gangrenous cholecystitis and transient hepatotoxicity associated with 6-mercaptopurine use.

• Diagnostic challenges: The absence of a highly specific or sensitive diagnostic test necessitates clinicopathological correlation, which can delay diagnosis and complicate treatment decisions, particularly in atypical presentations.

• Limited evidence for emerging therapies: Evidence supporting most pipeline agents — including obinutuzumab, obexelimab, CAR-T cell therapy, and cytokine-targeted biologics such as dupilumab and tocilizumab — remains early-stage, with robust phase 3 data yet to mature for the majority of these approaches.

• Gaps in coronary artery involvement data: Available evidence on treatment response in IgG4-related coronary artery disease is limited, as dedicated coronary imaging was not consistently obtained at sufficiently early timepoints post-treatment, and long-term follow-up data remain incomplete across published cohorts.

Reigniting the CD40L Pathway: A High-Stakes Autoimmune Play

The recent licensing agreement for SP001, an investigational anti-CD40L antibody, represents a significant strategic maneuver in the autoimmune therapeutic landscape. For Spero Therapeutics, this deal signifies a substantial commitment to a new therapeutic area, backed by a considerable financial investment and external funding. The CD40-CD40L pathway is a well-established target in immunology, crucial for orchestrating adaptive immune responses, and its blockade has shown promise in modulating various autoimmune pathologies, from reducing autoantibodies in lupus nephritis to delaying disease progression in models of autoimmune cholangitis.

However, the path for CD40L antagonists has been fraught with challenges. Previous clinical development of anti-CD40L antibodies was notably hampered by the occurrence of severe thromboembolic events, leading to the termination of trials. This historical safety signal remains a critical consideration for SP001's development. Despite these past hurdles, the current deal, coupled with ongoing Phase 2 trials for other CD40L antagonists in conditions like Type 1 Diabetes, suggests a renewed industry interest and a belief that these safety concerns can be mitigated, perhaps through refined molecular designs or a more targeted approach to specific indications.

Spero's initial focus on IgG4-related disease and Innovent's plans for Sjögren’s disease highlight a strategic selection of indications where the therapeutic benefits of CD40L blockade might outweigh the known risks. The broad immunomodulatory effects of this mechanism, while offering therapeutic potential, also necessitate careful monitoring for off-target effects or potential long-term immune suppression. The success of SP001 will hinge on its ability to demonstrate a favorable safety profile, particularly regarding thromboembolism, while delivering sustained efficacy in these chronic autoimmune conditions. This high-stakes endeavor could either validate the renewed confidence in CD40L blockade or underscore the persistent challenges of this complex pathway.